Stem cell treatment for liver cirrhosis in Republic of Korea — get 3 top clinic matches with costs

Stem cell treatment for liver cirrhosis in South Korea involves using mesenchymal stem cells to regenerate tissue and reduce fibrosis. Specialists typically perform direct arterial infusion. This targeted method delivers cells via a catheter into the hepatic artery. This delivers a higher cell concentration to the damaged liver than intravenous methods.

• Cell sources: Clinics use autologous bone marrow or adipose tissue to avoid rejection.
• Specialised techniques: RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) specialises in direct arterial infusion.
• Clinical protocols: Doctors like Dr Jin Yong Kim apply John Hopkins-standard gastrointestinal expertise.
• Safety standards: Facilities maintain KOIHA accreditation to meet international safety and quality benchmarks.

Bookimed Expert Insight: While many countries offer basic intravenous stem cells, South Korean clinics focus on arterial delivery. RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) limits intake to two patients daily. This VIP approach allows surgeons to map the liver's blood supply with extreme precision.

Patient Consensus: Patients often use this therapy as a bridge to transplant to improve their health. The process is a clinical regenerative therapy aimed at lowering scar tissue and boosting liver function.

South Korea manages stem cell therapies for liver cirrhosis through a strict dual-track system. This system operates under the Ministry of Food and Drug Safety (MFDS) and the Ministry of Health and Welfare. No stem cell drug is currently approved for commercial use in liver cirrhosis. However, patients can access treatment through authorised clinical trials or designated medical institutions. These are governed by the Advanced Regenerative Medicine Act.

• Regulatory framework: The MFDS and Ministry of Health and Welfare oversee all cellular clinical applications.
• Clinical pathways: Access is limited to government-authorised clinical trials or certified medical institutions only.
• Direct delivery: Specialised centres like RE:YOUTH use arterial infusion to deliver cells directly to the liver.
• Safety standards: Facilities must strictly follow Good Manufacturing Practice (GMP) standards to maintain cell viability.
• Therapy types: Research focuses on autologous bone marrow-derived mesenchymal stem cells to reduce liver fibrosis.

Bookimed Expert Insight: While many centres describe these treatments as available, they are technically investigational. Bookimed data shows high-tier clinics like RE:YOUTH limit intake to 2 daily patients. This is to meet strict VIP and safety protocols. This careful approach is a hallmark of the Korean system. Specialists like Dr Jin Yong Kim leave top university hospitals. They move into private regenerative practice.

Patient Consensus: Stem cell therapy for liver cirrhosis in South Korea is experimental. It is tied to specific hospital trials. Patients find that accessing legitimate treatment requires formal referrals rather than casual clinic shopping.

Stem cell therapy for liver cirrhosis in South Korea helps manage symptoms and slow disease progression but is not a complete cure. Specialists use mesenchymal stem cells via direct arterial infusion to reduce fibrosis. This treatment aims to regenerate surviving liver tissue rather than fully reversing end-stage cirrhosis.

• Treatment goals: Therapy focuses on reducing hepatic inflammation and breaking down existing scar tissue.
• Delivery: RE:YOUTH clinic uses arterial stem cell therapy to deliver cells directly to the liver.
• Clinical results: Patients often see improved albumin production and a better MELD score after treatment.
• Accredited facilities: Centres like RE:YOUTH hold KOIHA accreditation, meeting international safety and quality standards.
• Professional expertise: Board-certified gastroenterologists like Dr Min Jung Park oversee these regenerative procedures in Seoul.

Bookimed Expert Insight: While most clinics offer general injections, the specialised arterial infusion in Cheonan targets the liver directly. This method is rare and limited to just 2 patients per day. Choosing a clinic with this level of VIP focus leads to more precise cell delivery for complex cases.

Patient Consensus: Many patients describe the therapy as a vital bridge to transplant or a way to support recovery. Patients note significant energy boosts but suggest getting a second opinion from a hepatologist before booking.

Stem cell treatment for liver cirrhosis in South Korea is generally safe and well-tolerated. Most side effects are mild, such as temporary fever or fatigue. Notable risks such as bleeding or vascular injury usually stem from the arterial infusion process. They rarely come from the cells themselves.

• Infusion reactions: Patients may experience mild fever, chills, or headache shortly after the procedure.
• Arterial complications: Direct arterial infusion carries minor risks of local bruising, tenderness, or bleeding.
• Disease stability: Advanced cirrhosis patients might see temporary fluid accumulation during the recovery phase.
• Strict regulation: KOIHA-accredited clinics like RE:YOUTH use closed systems to prevent contamination and infection.

Bookimed Expert Insight: Specialist clinics in South Korea, such as RE:YOUTH in Cheonan, limit intake to only two patients daily. This VIP-level focus means doctors like Dr. Jin Yong Kim can manage clotting and bleeding risks closely. High-attention care is vital for patients with portal hypertension who require stable monitoring.

Patient Consensus: Travellers report mild flu-like symptoms and local swelling that resolve quickly. Patients often feel more confident knowing clinics explain long-term safety protocols for advanced liver disease.

South Korean clinics primarily use Mesenchymal Stem Cells (MSCs) to treat liver cirrhosis. Specialists often use autologous cells like the Cellgram-LC product. These cells come from the patient's own bone marrow or fat tissue. These cells reduce liver scarring and encourage new tissue growth.

• Mesenchymal Stem Cells: These primary cells reduce inflammation and support liver regeneration.
• Autologous source: Clinicians typically harvest cells from the patient's own bone marrow.
• Adipose source: Fat-derived stem cells provide high proliferative capacity for tissue repair.
• Arterial infusion: Specialists like Dr Min Jung Park use direct arterial delivery.
• Direct delivery: Direct infusion delivers cells to the liver with minimal cell loss.

Bookimed Expert Insight: Many countries use general intravenous drips. However, RE:YOUTH Clinic in South Korea specialises in arterial stem cell therapy. This method sends cells directly to the liver through the hepatic artery. Data shows this maximises cell concentration where it is needed most. Some clinics limit intake to two patients daily for this high-precision delivery.

Patient Consensus: Patients value how specialists use their own bone marrow cells to avoid rejection risks. The focused arterial approach in South Korea provides a sense of targeted, intensive care.